ID   RYR3_HUMAN              Reviewed;        4870 AA.
AC   Q15413; O15175; Q15412;
DT   26-SEP-2001, integrated into UniProtKB/Swiss-Prot.
DT   08-MAR-2011, sequence version 3.
DT   22-FEB-2023, entry version 205.
DE   RecName: Full=Ryanodine receptor 3;
DE            Short=RYR-3;
DE            Short=RyR3;
DE   AltName: Full=Brain ryanodine receptor-calcium release channel;
DE   AltName: Full=Brain-type ryanodine receptor;
DE   AltName: Full=Type 3 ryanodine receptor;
GN   Name=RYR3; Synonyms=HBRR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=9395096; DOI=10.1016/s0014-5793(97)01275-1;
RA   Nakashima Y., Nishimura S., Maeda A., Barsoumian E.L., Hakamata Y.,
RA   Nakai J., Allen P.D., Imoto K., Kita T.;
RT   "Molecular cloning and characterization of a human brain ryanodine
RT   receptor.";
RL   FEBS Lett. 417:157-162(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ALTERNATIVE SPLICING, AND VARIANTS
RP   SER-261; ILE-494; CYS-693; VAL-731; GLY-1380 AND SER-2268 DEL.
RC   TISSUE=Fetal brain;
RX   PubMed=9515741; DOI=10.1016/s0014-5793(98)00124-0;
RA   Leeb T., Brenig B.;
RT   "cDNA cloning and sequencing of the human ryanodine receptor type 3 (RYR3)
RT   reveals a novel alternative splice site in the RYR3 gene.";
RL   FEBS Lett. 423:367-370(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 520-660, AND TISSUE SPECIFICITY.
RC   TISSUE=Skeletal muscle;
RX   PubMed=9607712; DOI=10.1016/s0306-4522(97)00612-x;
RA   Martin C., Chapman K.E., Seckl J.R., Ashley R.H.;
RT   "Partial cloning and differential expression of ryanodine receptor/calcium-
RT   release channel genes in human tissues including the hippocampus and
RT   cerebellum.";
RL   Neuroscience 85:205-216(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3943-4870.
RC   TISSUE=T-cell;
RX   PubMed=7523185; DOI=10.1016/0014-5793(94)00955-4;
RA   Hakamata Y., Nishimura S., Nakai J., Nakashima Y., Kita T., Imoto K.;
RT   "Involvement of the brain type of ryanodine receptor in T-cell
RT   proliferation.";
RL   FEBS Lett. 352:206-210(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 4644-4842.
RC   TISSUE=Cervix carcinoma, and Hepatoma;
RX   PubMed=8276408; DOI=10.1006/geno.1993.1446;
RA   Sorrentino V., Giannini G., Malzac P., Mattei M.-G.;
RT   "Localization of a novel ryanodine receptor gene (RYR3) to human chromosome
RT   15q14-q15 by in situ hybridization.";
RL   Genomics 18:163-165(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4652-4803.
RC   TISSUE=Myometrium;
RX   PubMed=7556644; DOI=10.1016/0014-5793(95)00924-x;
RA   Lynn S., Morgan J.M., Lamb H.K., Meissner G., Gillespie J.I.;
RT   "Isolation and partial cloning of ryanodine-sensitive Ca2+ release channel
RT   protein isoforms from human myometrial smooth muscle.";
RL   FEBS Lett. 372:6-12(1995).
RN   [8]
RP   FUNCTION.
RX   PubMed=12354756; DOI=10.1074/jbc.m209061200;
RA   Schwarzmann N., Kunerth S., Weber K., Mayr G.W., Guse A.H.;
RT   "Knock-down of the type 3 ryanodine receptor impairs sustained Ca2+
RT   signaling via the T cell receptor/CD3 complex.";
RL   J. Biol. Chem. 277:50636-50642(2002).
RN   [9]
RP   INTERACTION WITH FKBP1A.
RX   PubMed=22100703; DOI=10.1016/j.abb.2011.11.004;
RA   Wen H., Kang S., Song Y., Song Y., Yang H.J., Kim M.H., Park S.;
RT   "Characterization of the binding sites for the interactions between FKBP12
RT   and intracellular calcium release channels.";
RL   Arch. Biochem. Biophys. 517:37-42(2012).
RN   [10] {ECO:0007744|PDB:4ERV}
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 2597-2800.
RX   PubMed=22705209; DOI=10.1016/j.str.2012.04.015;
RA   Yuchi Z., Lau K., Van Petegem F.;
RT   "Disease mutations in the ryanodine receptor central region: crystal
RT   structures of a phosphorylation hot spot domain.";
RL   Structure 20:1201-1211(2012).
CC   -!- FUNCTION: Calcium channel that mediates the release of Ca(2+) from the
CC       sarcoplasmic reticulum into the cytoplasm in muscle and thereby plays a
CC       role in triggering muscle contraction. May regulate Ca(2+) release by
CC       other calcium channels. Calcium channel that mediates Ca(2+)-induced
CC       Ca(2+) release from the endoplasmic reticulum in non-muscle cells.
CC       Contributes to cellular calcium ion homeostasis (By similarity). Plays
CC       a role in cellular calcium signaling. {ECO:0000250,
CC       ECO:0000269|PubMed:12354756}.
CC   -!- SUBUNIT: Homotetramer. Heterotetramer with RYR2. Interacts with CALM
CC       (By similarity). Interacts with FKBP1A. Interacts with SELENON (By
CC       similarity). {ECO:0000250|UniProtKB:Q9TS33,
CC       ECO:0000269|PubMed:22100703}.
CC   -!- SUBCELLULAR LOCATION: Sarcoplasmic reticulum membrane {ECO:0000305};
CC       Multi-pass membrane protein {ECO:0000305}. Membrane {ECO:0000305};
CC       Multi-pass membrane protein {ECO:0000305}. Microsome membrane
CC       {ECO:0000250}; Multi-pass membrane protein {ECO:0000250}. Sarcoplasmic
CC       reticulum {ECO:0000250|UniProtKB:Q9TS33}. Note=The number of predicted
CC       transmembrane domains varies between orthologs, but both N-terminus and
CC       C-terminus seem to be cytoplasmic. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q15413-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15413-2; Sequence=VSP_005954;
CC       Name=3;
CC         IsoId=Q15413-3; Sequence=VSP_005955, VSP_005956;
CC   -!- TISSUE SPECIFICITY: Brain, skeletal muscle, placenta and possibly liver
CC       and kidney. In brain, highest levels are found in the cerebellum,
CC       hippocampus, caudate nucleus and amygdala, with lower levels in the
CC       corpus callosum, substantia nigra and thalamus.
CC       {ECO:0000269|PubMed:9395096, ECO:0000269|PubMed:9607712}.
CC   -!- DOMAIN: The calcium release channel activity resides in the C-terminal
CC       region while the remaining part of the protein resides in the
CC       cytoplasm. {ECO:0000305}.
CC   -!- MISCELLANEOUS: Channel activity is modulated by the alkaloid ryanodine
CC       that binds to the open calcium-release channel with high affinity. At
CC       low concentrations, ryanodine maintains the channel in an open
CC       conformation. High ryanodine concentrations inhibit channel activity.
CC       Channel activity is regulated by calmodulin (CALM). The calcium release
CC       is activated by elevated cytoplasmic calcium levels in the micromolar
CC       range, by caffeine and adenine nucleotides, such as AMP and ATP.
CC       Inhibited by Mg(2+) and ruthenium red (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the ryanodine receptor (TC 1.A.3.1) family. RYR3
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA23795.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Ryanodine receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Ryanodine_receptor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB001025; BAA23795.1; ALT_FRAME; mRNA.
DR   EMBL; AJ001515; CAA04798.1; -; mRNA.
DR   EMBL; AC010809; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC011938; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC055874; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC067793; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087638; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AJ002512; CAA05503.1; -; mRNA.
DR   EMBL; X74269; CAA52326.1; -; mRNA.
DR   EMBL; X74270; CAA52327.1; -; Genomic_DNA.
DR   CCDS; CCDS45210.1; -. [Q15413-1]
DR   CCDS; CCDS58351.1; -. [Q15413-2]
DR   PIR; S37537; S37537.
DR   PIR; S66631; S66631.
DR   RefSeq; NP_001027.3; NM_001036.4. [Q15413-1]
DR   RefSeq; NP_001230925.1; NM_001243996.2. [Q15413-2]
DR   PDB; 4ERV; X-ray; 1.75 A; A=2597-2800.
DR   PDB; 6UHA; X-ray; 2.85 A; A/B=848-1055.
DR   PDB; 6UHB; X-ray; 2.50 A; A/B=848-1055.
DR   PDB; 6UHE; X-ray; 2.89 A; A/B/C/D=848-1055.
DR   PDB; 6UHH; X-ray; 3.14 A; A/B/C/D=848-1055.
DR   PDBsum; 4ERV; -.
DR   PDBsum; 6UHA; -.
DR   PDBsum; 6UHB; -.
DR   PDBsum; 6UHE; -.
DR   PDBsum; 6UHH; -.
DR   SMR; Q15413; -.
DR   BioGRID; 112175; 15.
DR   ComplexPortal; CPX-3162; Ryanodine 3 complex.
DR   IntAct; Q15413; 6.
DR   STRING; 9606.ENSP00000373884; -.
DR   ChEMBL; CHEMBL2062; -.
DR   DrugBank; DB11093; Calcium citrate.
DR   DrugBank; DB11348; Calcium Phosphate.
DR   DrugBank; DB14481; Calcium phosphate dihydrate.
DR   DrugCentral; Q15413; -.
DR   GlyCosmos; Q15413; 2 sites, 1 glycan.
DR   GlyGen; Q15413; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q15413; -.
DR   PhosphoSitePlus; Q15413; -.
DR   SwissPalm; Q15413; -.
DR   BioMuta; RYR3; -.
DR   DMDM; 325511382; -.
DR   EPD; Q15413; -.
DR   MassIVE; Q15413; -.
DR   PaxDb; Q15413; -.
DR   PeptideAtlas; Q15413; -.
DR   ProteomicsDB; 60577; -. [Q15413-1]
DR   ProteomicsDB; 60578; -. [Q15413-2]
DR   ProteomicsDB; 60579; -. [Q15413-3]
DR   Antibodypedia; 41923; 41 antibodies from 17 providers.
DR   DNASU; 6263; -.
DR   Ensembl; ENST00000415757.7; ENSP00000399610.3; ENSG00000198838.14. [Q15413-2]
DR   Ensembl; ENST00000634891.2; ENSP00000489262.1; ENSG00000198838.14. [Q15413-1]
DR   GeneID; 6263; -.
DR   KEGG; hsa:6263; -.
DR   MANE-Select; ENST00000634891.2; ENSP00000489262.1; NM_001036.6; NP_001027.3.
DR   UCSC; uc001zhi.3; human. [Q15413-1]
DR   AGR; HGNC:10485; -.
DR   CTD; 6263; -.
DR   DisGeNET; 6263; -.
DR   GeneCards; RYR3; -.
DR   HGNC; HGNC:10485; RYR3.
DR   HPA; ENSG00000198838; Tissue enhanced (brain, choroid plexus, skeletal muscle, tongue).
DR   MIM; 180903; gene.
DR   neXtProt; NX_Q15413; -.
DR   OpenTargets; ENSG00000198838; -.
DR   PharmGKB; PA34897; -.
DR   VEuPathDB; HostDB:ENSG00000198838; -.
DR   eggNOG; KOG2243; Eukaryota.
DR   GeneTree; ENSGT00940000155507; -.
DR   HOGENOM; CLU_000040_2_0_1; -.
DR   InParanoid; Q15413; -.
DR   OMA; LMQSCRS; -.
DR   OrthoDB; 3144451at2759; -.
DR   PhylomeDB; Q15413; -.
DR   TreeFam; TF315244; -.
DR   PathwayCommons; Q15413; -.
DR   Reactome; R-HSA-2672351; Stimuli-sensing channels.
DR   Reactome; R-HSA-5578775; Ion homeostasis.
DR   SignaLink; Q15413; -.
DR   BioGRID-ORCS; 6263; 16 hits in 1150 CRISPR screens.
DR   ChiTaRS; RYR3; human.
DR   GeneWiki; RYR3; -.
DR   GenomeRNAi; 6263; -.
DR   Pharos; Q15413; Tclin.
DR   PRO; PR:Q15413; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q15413; protein.
DR   Bgee; ENSG00000198838; Expressed in diaphragm and 146 other tissues.
DR   ExpressionAtlas; Q15413; baseline and differential.
DR   Genevisible; Q15413; HS.
DR   GO; GO:0034704; C:calcium channel complex; IBA:GO_Central.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0042383; C:sarcolemma; IBA:GO_Central.
DR   GO; GO:0016529; C:sarcoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; ISS:UniProtKB.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IBA:GO_Central.
DR   GO; GO:0030018; C:Z disc; IBA:GO_Central.
DR   GO; GO:0005509; F:calcium ion binding; IBA:GO_Central.
DR   GO; GO:0048763; F:calcium-induced calcium release activity; IBA:GO_Central.
DR   GO; GO:0015278; F:calcium-release channel activity; IMP:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0005219; F:ryanodine-sensitive calcium-release channel activity; ISS:UniProtKB.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; ISS:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; IMP:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:InterPro.
DR   GO; GO:0071318; P:cellular response to ATP; ISS:UniProtKB.
DR   GO; GO:0071313; P:cellular response to caffeine; ISS:UniProtKB.
DR   GO; GO:0071277; P:cellular response to calcium ion; ISS:UniProtKB.
DR   GO; GO:0071286; P:cellular response to magnesium ion; ISS:UniProtKB.
DR   GO; GO:0051289; P:protein homotetramerization; ISS:UniProtKB.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IBA:GO_Central.
DR   CDD; cd12877; SPRY1_RyR; 1.
DR   CDD; cd12878; SPRY2_RyR; 1.
DR   CDD; cd12879; SPRY3_RyR; 1.
DR   Gene3D; 1.10.287.70; -; 1.
DR   Gene3D; 1.10.490.160; -; 2.
DR   Gene3D; 2.60.120.920; -; 3.
DR   Gene3D; 2.80.10.50; -; 2.
DR   Gene3D; 6.20.350.10; -; 1.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   Gene3D; 1.25.10.30; IP3 receptor type 1 binding core, RIH domain; 1.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR001870; B30.2/SPRY.
DR   InterPro; IPR043136; B30.2/SPRY_sf.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR014821; Ins145_P3_rcpt.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR036300; MIR_dom_sf.
DR   InterPro; IPR016093; MIR_motif.
DR   InterPro; IPR013662; RIH_assoc-dom.
DR   InterPro; IPR000699; RIH_dom.
DR   InterPro; IPR013333; Ryan_recept.
DR   InterPro; IPR015925; Ryanodine_IP3_receptor.
DR   InterPro; IPR003032; Ryanodine_rcpt.
DR   InterPro; IPR009460; Ryanrecept_TM4-6.
DR   InterPro; IPR035910; RyR/IP3R_RIH_dom_sf.
DR   InterPro; IPR035761; SPRY1_RyR.
DR   InterPro; IPR035764; SPRY2_RyR.
DR   InterPro; IPR035762; SPRY3_RyR.
DR   InterPro; IPR003877; SPRY_dom.
DR   PANTHER; PTHR46399; B30.2/SPRY DOMAIN-CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR46399:SF9; RYANODINE RECEPTOR 3; 1.
DR   Pfam; PF08709; Ins145_P3_rec; 1.
DR   Pfam; PF00520; Ion_trans; 1.
DR   Pfam; PF02815; MIR; 1.
DR   Pfam; PF08454; RIH_assoc; 1.
DR   Pfam; PF06459; RR_TM4-6; 1.
DR   Pfam; PF01365; RYDR_ITPR; 2.
DR   Pfam; PF02026; RyR; 4.
DR   Pfam; PF00622; SPRY; 3.
DR   PRINTS; PR00795; RYANODINER.
DR   SMART; SM00472; MIR; 4.
DR   SMART; SM00449; SPRY; 3.
DR   SUPFAM; SSF48371; ARM repeat; 1.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 3.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   SUPFAM; SSF100909; IP3 receptor type 1 binding core, domain 2; 1.
DR   SUPFAM; SSF82109; MIR domain; 2.
DR   PROSITE; PS50188; B302_SPRY; 3.
DR   PROSITE; PS50919; MIR; 5.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Calcium channel;
KW   Calcium transport; Calmodulin-binding; Endoplasmic reticulum; Ion channel;
KW   Ion transport; Ligand-gated ion channel; Membrane; Microsome; Receptor;
KW   Reference proteome; Repeat; Sarcoplasmic reticulum; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..4870
FT                   /note="Ryanodine receptor 3"
FT                   /id="PRO_0000219363"
FT   TOPO_DOM        1..4186
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        4187..4207
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4410..4430
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4485..4505
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4610..4630
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4633..4653
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4672..4692
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   INTRAMEM        4723..4732
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        4753..4773
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        4774..4870
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   DOMAIN          100..155
FT                   /note="MIR 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          162..207
FT                   /note="MIR 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          215..269
FT                   /note="MIR 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          275..333
FT                   /note="MIR 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          343..400
FT                   /note="MIR 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          585..796
FT                   /note="B30.2/SPRY 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          840..953
FT                   /note="1"
FT   REPEAT          954..1068
FT                   /note="2"
FT   DOMAIN          1012..1208
FT                   /note="B30.2/SPRY 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   DOMAIN          1254..1466
FT                   /note="B30.2/SPRY 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          2589..2707
FT                   /note="3"
FT   REPEAT          2708..2820
FT                   /note="4"
FT   REGION          840..2820
FT                   /note="4 X approximate repeats"
FT   REGION          2322..2335
FT                   /note="Interaction with FKBP1A"
FT                   /evidence="ECO:0000269|PubMed:22100703"
FT   REGION          3469..3498
FT                   /note="Interaction with CALM"
FT                   /evidence="ECO:0000250"
FT   REGION          4102..4121
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          4304..4360
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4315..4360
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            3883
FT                   /note="Important for activation by Ca(2+)"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         3337..3341
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9395096"
FT                   /id="VSP_005954"
FT   VAR_SEQ         3857..3859
FT                   /note="DSS -> GMW (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_005955"
FT   VAR_SEQ         3860..4870
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_005956"
FT   VARIANT         261
FT                   /note="R -> S"
FT                   /evidence="ECO:0000269|PubMed:9515741"
FT                   /id="VAR_024077"
FT   VARIANT         358
FT                   /note="I -> T (in dbSNP:rs2304380)"
FT                   /id="VAR_057166"
FT   VARIANT         494
FT                   /note="V -> I (in dbSNP:rs2077268)"
FT                   /evidence="ECO:0000269|PubMed:9515741"
FT                   /id="VAR_024078"
FT   VARIANT         693
FT                   /note="Y -> C"
FT                   /evidence="ECO:0000269|PubMed:9515741"
FT                   /id="VAR_011404"
FT   VARIANT         731
FT                   /note="I -> V (in dbSNP:rs2229116)"
FT                   /evidence="ECO:0000269|PubMed:9515741"
FT                   /id="VAR_011405"
FT   VARIANT         1380
FT                   /note="E -> G"
FT                   /evidence="ECO:0000269|PubMed:9515741"
FT                   /id="VAR_011406"
FT   VARIANT         2268
FT                   /note="Missing"
FT                   /evidence="ECO:0000269|PubMed:9515741"
FT                   /id="VAR_011407"
FT   CONFLICT        932
FT                   /note="A -> T (in Ref. 1; BAA23795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1081
FT                   /note="A -> P (in Ref. 1; BAA23795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1336
FT                   /note="A -> G (in Ref. 1; BAA23795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1480
FT                   /note="K -> E (in Ref. 1; BAA23795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1641
FT                   /note="R -> C (in Ref. 1; BAA23795 and 2; CAA04798)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2270
FT                   /note="G -> E (in Ref. 1; BAA23795 and 2; CAA04798)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2355
FT                   /note="A -> G (in Ref. 1; BAA23795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2433
FT                   /note="A -> G (in Ref. 1; BAA23795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2546
FT                   /note="F -> I (in Ref. 1; BAA23795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2580
FT                   /note="T -> S (in Ref. 1; BAA23795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2817
FT                   /note="A -> G (in Ref. 1; BAA23795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3684
FT                   /note="S -> P (in Ref. 1; BAA23795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3698
FT                   /note="F -> S (in Ref. 1; BAA23795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4026
FT                   /note="E -> G (in Ref. 1; BAA23795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4083
FT                   /note="E -> G (in Ref. 1; BAA23795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4537
FT                   /note="R -> P (in Ref. 1; BAA23795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4604
FT                   /note="I -> L (in Ref. 1; BAA23795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4709
FT                   /note="C -> R (in Ref. 6; CAA52326)"
FT                   /evidence="ECO:0000305"
FT   HELIX           863..865
FT                   /evidence="ECO:0007829|PDB:6UHB"
FT   HELIX           866..886
FT                   /evidence="ECO:0007829|PDB:6UHB"
FT   TURN            897..900
FT                   /evidence="ECO:0007829|PDB:6UHB"
FT   HELIX           908..910
FT                   /evidence="ECO:0007829|PDB:6UHB"
FT   HELIX           913..932
FT                   /evidence="ECO:0007829|PDB:6UHB"
FT   STRAND          936..938
FT                   /evidence="ECO:0007829|PDB:6UHB"
FT   HELIX           944..947
FT                   /evidence="ECO:0007829|PDB:6UHB"
FT   HELIX           955..957
FT                   /evidence="ECO:0007829|PDB:6UHB"
FT   HELIX           977..1000
FT                   /evidence="ECO:0007829|PDB:6UHB"
FT   TURN            1011..1014
FT                   /evidence="ECO:0007829|PDB:6UHB"
FT   HELIX           1022..1024
FT                   /evidence="ECO:0007829|PDB:6UHB"
FT   HELIX           1027..1046
FT                   /evidence="ECO:0007829|PDB:6UHB"
FT   STRAND          1050..1052
FT                   /evidence="ECO:0007829|PDB:6UHB"
FT   HELIX           2612..2635
FT                   /evidence="ECO:0007829|PDB:4ERV"
FT   TURN            2646..2649
FT                   /evidence="ECO:0007829|PDB:4ERV"
FT   HELIX           2657..2659
FT                   /evidence="ECO:0007829|PDB:4ERV"
FT   HELIX           2662..2681
FT                   /evidence="ECO:0007829|PDB:4ERV"
FT   STRAND          2685..2688
FT                   /evidence="ECO:0007829|PDB:4ERV"
FT   HELIX           2695..2704
FT                   /evidence="ECO:0007829|PDB:4ERV"
FT   HELIX           2723..2725
FT                   /evidence="ECO:0007829|PDB:4ERV"
FT   HELIX           2730..2757
FT                   /evidence="ECO:0007829|PDB:4ERV"
FT   HELIX           2769..2771
FT                   /evidence="ECO:0007829|PDB:4ERV"
FT   HELIX           2774..2792
FT                   /evidence="ECO:0007829|PDB:4ERV"
FT   TURN            2793..2795
FT                   /evidence="ECO:0007829|PDB:4ERV"
FT   STRAND          2796..2799
FT                   /evidence="ECO:0007829|PDB:4ERV"
SQ   SEQUENCE   4870 AA;  552042 MW;  B953487A89FD480F CRC64;
     MAEGGEGGED EIQFLRTEDE VVLQCIATIH KEQRKFCLAA EGLGNRLCFL EPTSEAKYIP
     PDLCVCNFVL EQSLSVRALQ EMLANTGENG GEGAAQGGGH RTLLYGHAVL LRHSFSGMYL
     TCLTTSRSQT DKLAFDVGLR EHATGEACWW TIHPASKQRS EGEKVRIGDD LILVSVSSER
     YLHLSVSNGN IQVDASFMQT LWNVHPTCSG SSIEEGYLLG GHVVRLFHGH DECLTIPSTD
     QNDSQHRRIF YEAGGAGTRA RSLWRVEPLR ISWSGSNIRW GQAFRLRHLT TGHYLALTED
     QGLILQDRAK SDTKSTAFSF RASKELKEKL DSSHKRDIEG MGVPEIKYGD SVCFVQHIAS
     GLWVTYKAQD AKTSRLGPLK RKVILHQEGH MDDGLTLQRC QREESQAARI IRNTTALFSQ
     FVSGNNRTAA PITLPIEEVL QTLQDLIAYF QPPEEEMRHE DKQNKLRSLK NRQNLFKEEG
     MLALVLNCID RLNVYNSVAH FAGIAREESG MAWKEILNLL YKLLAALIRG NRNNCAQFSN
     NLDWLISKLD RLESSSGILE VLHCILTESP EALNLIAEGH IKSIISLLDK HGRNHKVLDI
     LCSLCLCNGV AVRANQNLIC DNLLPRRNLL LQTRLINDVT SIRPNIFLGV AEGSAQYKKW
     YFELIIDQVD PFLTAEPTHL RVGWASSSGY APYPGGGEGW GGNGVGDDLY SYGFDGLHLW
     SGRIPRAVAS INQHLLRSDD VVSCCLDLGV PSISFRINGQ PVQGMFENFN TDGLFFPVMS
     FSAGVKVRFL MGGRHGEFKF LPPSGYAPCY EALLPKEKMR LEPVKEYKRD ADGIRDLLGT
     TQFLSQASFI PCPVDTSQVI LPPHLEKIRD RLAENIHELW GMNKIELGWT FGKIRDDNKR
     QHPCLVEFSK LPETEKNYNL QMSTETLKTL LALGCHIAHV NPAAEEDLKK VKLPKNYMMS
     NGYKPAPLDL SDVKLLPPQE ILVDKLAENA HNVWAKDRIK QGWTYGIQQD LKNKRNPRLV
     PYALLDERTK KSNRDSLREA VRTFVGYGYN IEPSDQELAD SAVEKVSIDK IRFFRVERSY
     AVRSGKWYFE FEVVTGGDMR VGWARPGCRP DVELGADDQA FVFEGNRGQR WHQGSGYFGR
     TWQPGDVVGC MINLDDASMI FTLNGELLIT NKGSELAFAD YEIENGFVPI CCLGLSQIGR
     MNLGTDASTF KFYTMCGLQE GFEPFAVNMN RDVAMWFSKR LPTFVNVPKD HPHIEVMRID
     GTMDSPPCLK VTHKTFGTQN SNADMIYCRL SMPVECHSSF SHSPCLDSEA FQKRKQMQEI
     LSHTTTQCYY AIRIFAGQDP SCVWVGWVTP DYHLYSEKFD LNKNCTVTVT LGDERGRVHE
     SVKRSNCYMV WGGDIVASSQ RSNRSNVDLE IGCLVDLAMG MLSFSANGKE LGTCYQVEPN
     TKVFPAVFLQ PTSTSLFQFE LGKLKNAMPL SAAIFRSEEK NPVPQCPPRL DVQTIQPVLW
     SRMPNSFLKV ETERVSERHG WVVQCLEPLQ MMALHIPEEN RCVDILELCE QEDLMRFHYH
     TLRLYSAVCA LGNSRVAYAL CSHVDLSQLF YAIDNKYLPG LLRSGFYDLL ISIHLASAKE
     RKLMMKNEYI IPITSTTRNI RLFPDESKRH GLPGVGLRTC LKPGFRFSTP CFVVTGEDHQ
     KQSPEIPLES LRTKALSMLT EAVQCSGAHI RDPVGGSVEF QFVPVLKLIG TLLVMGVFDD
     DDVRQILLLI DPSVFGEHSA GTEEGAEKEE VTQVEEKAVE AGEKAGKEAP VKGLLQTRLP
     ESVKLQMCEL LSYLCDCELQ HRVEAIVAFG DIYVSKLQAN QKFRYNELMQ ALNMSAALTA
     RKTKEFRSPP QEQINMLLNF QLGENCPCPE EIREELYDFH EDLLLHCGVP LEEEEEEEED
     TSWTGKLCAL VYKIKGPPKP EKEQPTEEEE RCPTTLKELI SQTMICWAQE DQIQDSELVR
     MMFNLLRRQY DSIGELLQAL RKTYTISHTS VSDTINLLAA LGQIRSLLSV RMGKEEELLM
     INGLGDIMNN KVFYQHPNLM RVLGMHETVM EVMVNVLGTE KSQIAFPKMV ASCCRFLCYF
     CRISRQNQKA MFEHLSYLLE NSSVGLASPS MRGSTPLDVA ASSVMDNNEL ALSLEEPDLE
     KVVTYLAGCG LQSCPMLLAK GYPDVGWNPI EGERYLSFLR FAVFVNSESV EENASVVVKL
     LIRRPECFGP ALRGEGGNGL LAAMQGAIKI SENPALDLPS QGYKREVSTG DDEEEEEIVH
     MGNAIMSFYS ALIDLLGRCA PEMHLIQTGK GEAIRIRSIL RSLVPTEDLV GIISIPLKLP
     SLNKDGSVSE PDMAANFCPD HKAPMVLFLD RVYGIKDQTF LLHLLEVGFL PDLRASASLD
     TVSLSTTEAA LALNRYICSA VLPLLTRCAP LFAGTEHCTS LIDSTLQTIY RLSKGRSLTK
     AQRDTIEECL LAICNHLRPS MLQQLLRRLV FDVPQLNEYC KMPLKLLTNH YEQCWKYYCL
     PSGWGSYGLA VEEELHLTEK LFWGIFDSLS HKKYDPDLFR MALPCLSAIA GALPPDYLDT
     RITATLEKQI SVDADGNFDP KPINTMNFSL PEKLEYIVTK YAEHSHDKWA CDKSQSGWKY
     GISLDENVKT HPLIRPFKTL TEKEKEIYRW PARESLKTML AVGWTVERTK EGEALVQQRE
     NEKLRSVSQA NQGNSYSPAP LDLSNVVLSR ELQGMVEVVA ENYHNIWAKK KKLELESKGG
     GSHPLLVPYD TLTAKEKFKD REKAQDLFKF LQVNGIIVSR GMKDMELDAS SMEKRFAYKF
     LKKILKYVDS AQEFIAHLEA IVSSGKTEKS PRDQEIKFFA KVLLPLVDQY FTSHCLYFLS
     SPLKPLSSSG YASHKEKEMV AGLFCKLAAL VRHRISLFGS DSTTMVSCLH ILAQTLDTRT
     VMKSGSELVK AGLRAFFENA AEDLEKTSEN LKLGKFTHSR TQIKGVSQNI NYTTVALLPI
     LTSIFEHVTQ HQFGMDLLLG DVQISCYHIL CSLYSLGTGK NIYVERQRPA LGECLASLAA
     AIPVAFLEPT LNRYNPLSVF NTKTPRERSI LGMPDTVEDM CPDIPQLEGL MKEINDLAES
     GARYTEMPHV IEVILPMLCN YLSYWWERGP ENLPPSTGPC CTKVTSEHLS LILGNILKII
     NNNLGIDEAS WMKRIAVYAQ PIISKARPDL LRSHFIPTLE KLKKKAVKTV QEEEQLKADG
     KGDTQEAELL ILDEFAVLCR DLYAFYPMLI RYVDNNRSNW LKSPDADSDQ LFRMVAEVFI
     LWCKSHNFKR EEQNFVIQNE INNLAFLTGD SKSKMSKAMQ VKSGGQDQER KKTKRRGDLY
     SIQTSLIVAA LKKMLPIGLN MCTPGDQELI SLAKSRYSHR DTDEEVREHL RNNLHLQEKS
     DDPAVKWQLN LYKDVLKSEE PFNPEKTVER VQRISAAVFH LEQVEQPLRS KKAVWHKLLS
     KQRKRAVVAC FRMAPLYNLP RHRSINLFLH GYQRFWIETE EYSFEEKLVQ DLAKSPKVEE
     EEEEETEKQP DPLHQIILYF SRNALTERSK LEDDPLYTSY SSMMAKSCQS GEDEEEDEDK
     EKTFEEKEME KQKTLYQQAR LHERGAAEMV LQMISASKGE MSPMVVETLK LGIAILNGGN
     AGVQQKMLDY LKEKKDAGFF QSLSGLMQSC SVLDLNAFER QNKAEGLGMV TEEGTLIVRE
     RGEKVLQNDE FTRDLFRFLQ LLCEGHNSDF QNFLRTQMGN TTTVNVIIST VDYLLRLQES
     ISDFYWYYSG KDIIDESGQH NFSKALAVTK QIFNSLTEYI QGPCIGNQQS LAHSRLWDAV
     VGFLHVFANM QMKLSQDSSQ IELLKELLDL LQDMVVMLLS LLEGNVVNGT IGKQMVDTLV
     ESSTNVEMIL KFFDMFLKLK DLTSSDTFKE YDPDGKGIIS KKEFQKAMEG QKQYTQSEID
     FLLSCAEADE NDMFNYVDFV DRFHEPAKDI GFNVAVLLTN LSEHMPNDSR LKCLLDPAES
     VLNYFEPYLG RIEIMGGAKK IERVYFEISE SSRTQWEKPQ VKESKRQFIF DVVNEGGEQE
     KMELFVNFCE DTIFEMQLAS QISESDSADR PEEEEEDEDS SYVLEIAGEE EEDGSLEPAS
     AFAMACASVK RNVTDFLKRA TLKNLRKQYR NVKKMTAKEL VKVLFSFFWM LFVGLFQLLF
     TILGGIFQIL WSTVFGGGLV EGAKNIRVTK ILGDMPDPTQ FGIHDDTMEA ERAEVMEPGI
     TTELVHFIKG EKGDTDIMSD LFGLHPKKEG SLKHGPEVGL GDLSEIIGKD EPPTLESTVQ
     KKRKAQAAEM KAANEAEGKV ESEKADMEDG EKEDKDKEEE QAEYLWTEVT KKKKRRCGQK
     VEKPEAFTAN FFKGLEIYQT KLLHYLARNF YNLRFLALFV AFAINFILLF YKVTEEPLEE
     ETEDVANLWN SFNDEEEEEA MVFFVLQEST GYMAPTLRAL AIIHTIISLV CVVGYYCLKV
     PLVVFKREKE IARKLEFDGL YITEQPSEDD IKGQWDRLVI NTPSFPNNYW DKFVKRKVIN
     KYGDLYGAER IAELLGLDKN ALDFSPVEET KAEAASLVSW LSSIDMKYHI WKLGVVFTDN
     SFLYLAWYTT MSVLGHYNNF FFAAHLLDIA MGFKTLRTIL SSVTHNGKQL VLTVGLLAVV
     VYLYTVVAFN FFRKFYNKSE DDDEPDMKCD DMMTCYLFHM YVGVRAGGGI GDEIEDPAGD
     PYEMYRIVFD ITFFFFVIVI LLAIIQGLII DAFGELRDQQ EQVREDMETK CFICGIGNDY
     FDTTPHGFET HTLQEHNLAN YLFFLMYLIN KDETEHTGQE SYVWKMYQER CWDFFPAGDC
     FRKQYEDQLG
//
